Cargando…
Cutaneous and hypersensitivity reactions associated with COVID-19 vaccination—a narrative review
Vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV‑2) has become a major tool in the battle against the coronavirus disease 2019 (COVID-19) pandemic. Numerous products have been developed and more are to come. Vaccination success varies greatly between different count...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381144/ https://www.ncbi.nlm.nih.gov/pubmed/34424434 http://dx.doi.org/10.1007/s10354-021-00876-0 |
_version_ | 1783741309293428736 |
---|---|
author | Wollina, Uwe Chiriac, Anca Kocic, Hristina Koch, André Brzezinski, Piotr |
author_facet | Wollina, Uwe Chiriac, Anca Kocic, Hristina Koch, André Brzezinski, Piotr |
author_sort | Wollina, Uwe |
collection | PubMed |
description | Vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV‑2) has become a major tool in the battle against the coronavirus disease 2019 (COVID-19) pandemic. Numerous products have been developed and more are to come. Vaccination success varies greatly between different countries. There are a number of different vaccine types, such as mRNA, DNA vaccines, adenovirus vector vaccines, and full-length spike protein nanoparticles with a special matrix. The different types may also cause a different spectrum of adverse events. With mass vaccination, post-marketing surveillance for product safety becomes increasingly important. In this review, we discuss possible hypersensitivity and cutaneous adverse events related to SARS-CoV‑2 vaccination—from local reactions like COVID arm to systemic and severe reactions like anaphylaxis. Vaccination may also induce or exacerbate preexisting disorders such as herpes zoster infection. This review should provide information to tailor, whenever possible, vaccination to patients’ needs. It is a contribution to patient safety as well. There is general consensus that the benefits of SARS-CoV‑2 vaccination currently outweigh the risks of possible adverse events. |
format | Online Article Text |
id | pubmed-8381144 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Vienna |
record_format | MEDLINE/PubMed |
spelling | pubmed-83811442021-08-23 Cutaneous and hypersensitivity reactions associated with COVID-19 vaccination—a narrative review Wollina, Uwe Chiriac, Anca Kocic, Hristina Koch, André Brzezinski, Piotr Wien Med Wochenschr Review Vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV‑2) has become a major tool in the battle against the coronavirus disease 2019 (COVID-19) pandemic. Numerous products have been developed and more are to come. Vaccination success varies greatly between different countries. There are a number of different vaccine types, such as mRNA, DNA vaccines, adenovirus vector vaccines, and full-length spike protein nanoparticles with a special matrix. The different types may also cause a different spectrum of adverse events. With mass vaccination, post-marketing surveillance for product safety becomes increasingly important. In this review, we discuss possible hypersensitivity and cutaneous adverse events related to SARS-CoV‑2 vaccination—from local reactions like COVID arm to systemic and severe reactions like anaphylaxis. Vaccination may also induce or exacerbate preexisting disorders such as herpes zoster infection. This review should provide information to tailor, whenever possible, vaccination to patients’ needs. It is a contribution to patient safety as well. There is general consensus that the benefits of SARS-CoV‑2 vaccination currently outweigh the risks of possible adverse events. Springer Vienna 2021-08-23 2022 /pmc/articles/PMC8381144/ /pubmed/34424434 http://dx.doi.org/10.1007/s10354-021-00876-0 Text en © Springer-Verlag GmbH Austria, ein Teil von Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Review Wollina, Uwe Chiriac, Anca Kocic, Hristina Koch, André Brzezinski, Piotr Cutaneous and hypersensitivity reactions associated with COVID-19 vaccination—a narrative review |
title | Cutaneous and hypersensitivity reactions associated with COVID-19 vaccination—a narrative review |
title_full | Cutaneous and hypersensitivity reactions associated with COVID-19 vaccination—a narrative review |
title_fullStr | Cutaneous and hypersensitivity reactions associated with COVID-19 vaccination—a narrative review |
title_full_unstemmed | Cutaneous and hypersensitivity reactions associated with COVID-19 vaccination—a narrative review |
title_short | Cutaneous and hypersensitivity reactions associated with COVID-19 vaccination—a narrative review |
title_sort | cutaneous and hypersensitivity reactions associated with covid-19 vaccination—a narrative review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381144/ https://www.ncbi.nlm.nih.gov/pubmed/34424434 http://dx.doi.org/10.1007/s10354-021-00876-0 |
work_keys_str_mv | AT wollinauwe cutaneousandhypersensitivityreactionsassociatedwithcovid19vaccinationanarrativereview AT chiriacanca cutaneousandhypersensitivityreactionsassociatedwithcovid19vaccinationanarrativereview AT kocichristina cutaneousandhypersensitivityreactionsassociatedwithcovid19vaccinationanarrativereview AT kochandre cutaneousandhypersensitivityreactionsassociatedwithcovid19vaccinationanarrativereview AT brzezinskipiotr cutaneousandhypersensitivityreactionsassociatedwithcovid19vaccinationanarrativereview |